Threshold Plummets As Merck Drops Evofosfamide For Sarcoma
This article was originally published in Scrip
Threshold Pharmaceuticals saw its stock lose more than 80% of its value following disappointing data from two Phase III trials of its anticancer evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. Its partner, Germany's Merck, said it would not be filing for approval of the product.
You may also be interested in...
Although a vehicle for Molecular Templates to take its Engineered Toxin Bodies oncology platform public, the combined company also will seek a pathway to approval for Threshold's evofosfamide for pancreatic cancer in Japan.
As questions remain over Merck KGAA's ability to retain its top line following the patent loss for its key products Rebif and Erbitux, the German company has highlighted some of its higher priority R&D programs in its "very interesting" pipeline, as well as its strategy to make the most of the assets.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.